{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Little MP"],"funding":["Intramural NIH HHS"],"pagination":["451-9"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3440544"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["85(2)"],"pubmed_abstract":["<h4>Purpose</h4>To assess the shape of the dose response for various cancer endpoints and modifiers by age and time.<h4>Methods and materials</h4>Reanalysis of the US peptic ulcer data testing for heterogeneity of radiogenic risk by cancer endpoint (stomach, pancreas, lung, leukemia, all other).<h4>Results</h4>There are statistically significant (P<.05) excess risks for all cancer and for lung cancer and borderline statistically significant risks for stomach cancer (P=.07), and leukemia (P=.06), with excess relative risks Gy(-1) of 0.024 (95% confidence interval [CI] 0.011, 0.039), 0.559 (95% CI 0.221, 1.021), 0.042 (95% CI -0.002, 0.119), and 1.087 (95% CI -0.018, 4.925), respectively. There is statistically significant (P=.007) excess risk of pancreatic cancer when adjusted for dose-resp"],"journal":["International journal of radiation oncology, biology, physics"],"pubmed_title":["A reanalysis of curvature in the dose response for cancer and modifications by age at exposure following radiation therapy for benign disease."],"pmcid":["PMC3440544"],"funding_grant_id":["Z99 CA999999"],"pubmed_authors":["Smith SA","Kleinerman RA","Stovall M","Little MP"],"additional_accession":[]},"is_claimable":false,"name":"A reanalysis of curvature in the dose response for cancer and modifications by age at exposure following radiation therapy for benign disease.","description":"<h4>Purpose</h4>To assess the shape of the dose response for various cancer endpoints and modifiers by age and time.<h4>Methods and materials</h4>Reanalysis of the US peptic ulcer data testing for heterogeneity of radiogenic risk by cancer endpoint (stomach, pancreas, lung, leukemia, all other).<h4>Results</h4>There are statistically significant (P<.05) excess risks for all cancer and for lung cancer and borderline statistically significant risks for stomach cancer (P=.07), and leukemia (P=.06), with excess relative risks Gy(-1) of 0.024 (95% confidence interval [CI] 0.011, 0.039), 0.559 (95% CI 0.221, 1.021), 0.042 (95% CI -0.002, 0.119), and 1.087 (95% CI -0.018, 4.925), respectively. There is statistically significant (P=.007) excess risk of pancreatic cancer when adjusted for dose-resp","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Feb","modification":"2025-04-04T08:09:03.096Z","creation":"2019-03-26T23:05:12Z"},"accession":"S-EPMC3440544","cross_references":{"pubmed":["22682810"],"doi":["10.1016/j.ijrobp.2012.04.029"]}}